Sorafenib inhibits lymphoma xenografts by targeting MAPK/ERK and AKT pathways in tumor and vascular cells.

Sorafenib inhibits lymphoma xenografts by targeting MAPK/ERK and AKT pathways in tumor and vascular cells.

The anti-lymphoma activity and mechanism(s) of action of the multikinase inhibitor sorafenib were investigated using a panel of lymphoma cell lines, including SU-DHL-4V, Granta-519, HD-MyZ, and KMS-11 cell lines. In vitro, sorafenib significantly decreased cell proliferation and phosphorylation leve...

Full description

Bibliographic Details
Main Authors: Carmelo Carlo-Stella, Silvia L Locatelli, Arianna Giacomini, Loredana Cleris, Elena Saba, Marco Righi, Anna Guidetti, Alessandro M Gianni
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2013-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3631141?pdf=render

Internet

http://europepmc.org/articles/PMC3631141?pdf=render

Similar Items